Literature DB >> 24500284

National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

Tobias Gerhard1, Ayse Akincigil, Christoph U Correll, Neil J Foglio, Stephen Crystal, Mark Olfson.   

Abstract

OBJECTIVE: This study estimates national trends and patterns in use of second-generation antipsychotics (SGAs) for adjunctive treatment of nonpsychotic adult depression in office-based practice.
METHOD: Twelve consecutive years (1999-2010) of the National Ambulatory Medical Care Survey were analyzed to estimate trends and patterns of adjunctive SGA treatment for adult (≥ 18 years) nonpsychotic depression in office-based visits. Adjunctive SGA use was examined among all office visits in which depression was diagnosed (N = 7,767), excluding visits with diagnoses for alternative SGA indications (schizophrenia, bipolar disorder, pervasive development disorder, psychotic depression, dementia) and those without an active antidepressant prescription.
RESULTS: From 1999 to 2010, 8.6% of adult depression visits included an SGA. SGA use rates increased from 4.6% in 1999-2000 to 12.5% in 2009-2010, with an adjusted odds ratio (AOR) for time trend of 2.78 (95% CI, 1.84-4.20). The increase in SGA augmentation was broad-based, with no significant differences in time trends between demographic and clinical subgroups. For the most recent survey years (2005-2010), SGA use rates were higher in visits to psychiatrists than to other physicians (AOR = 5.08; 95% CI, 2.96-8.73), visits covered by public than private insurance (AOR = 3.20; 95% CI, 2.25-4.54), visits with diagnosed major depressive disorder than other depressive disorders (AOR = 1.49; 95% CI, 1.08-2.06), and visits with diabetes, hyperlipidemia, or cardiovascular disease (AOR = 2.13; 95% CI, 1.12-4.03) and lower in visits by patients > 65 years than 18-44 years (AOR = 0.51; 95% CI, 0.32-0.82) and visits that included psychotherapy (AOR = 0.68; 95% CI, 0.47-0.96).
CONCLUSIONS: Between 1999 and 2010, SGAs were increasingly accepted in the outpatient treatment of adult nonpsychotic depression. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24500284      PMCID: PMC8215591          DOI: 10.4088/JCP.13m08675

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  54 in total

1.  Guide to using masked design variables to estimate standard errors in public use files of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey.

Authors:  Esther Hing; Sarah Gousen; Iris Shimizu; Catharine Burt
Journal:  Inquiry       Date:  2003       Impact factor: 1.730

Review 2.  Antipsychotic drugs and obesity.

Authors:  Christoph U Correll; Todd Lencz; Anil K Malhotra
Journal:  Trends Mol Med       Date:  2010-12-22       Impact factor: 11.951

Review 3.  Antidepressant combinations: widely used, but far from empirically validated.

Authors:  Michael E Thase
Journal:  Can J Psychiatry       Date:  2011-06       Impact factor: 4.356

4.  Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

Authors:  Richard C Shelton; Douglas J Williamson; Sara A Corya; Todd M Sanger; Luann E Van Campen; Michael Case; Susan D Briggs; Gary D Tollefson
Journal:  J Clin Psychiatry       Date:  2005-10       Impact factor: 4.384

5.  Antipsychotic use and myocardial infarction in older patients with treated dementia.

Authors:  Antoine Pariente; Annie Fourrier-Réglat; Thierry Ducruet; Paddy Farrington; Sarah-Gabrielle Béland; Jean-François Dartigues; Nicholas Moore; Yola Moride
Journal:  Arch Intern Med       Date:  2012-03-26

Review 6.  Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

7.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

8.  Management of access to branded psychotropic medications in private health plans.

Authors:  Dominic Hodgkin; Constance M Horgan; Deborah W Garnick; Elizabeth Len Merrick; Joanna Volpe-Vartanian
Journal:  Clin Ther       Date:  2007-02       Impact factor: 3.393

Review 9.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

10.  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

Authors:  J Craig Nelson; George I Papakostas
Journal:  Am J Psychiatry       Date:  2009-08-17       Impact factor: 18.112

View more
  9 in total

1.  Mental health service use for adult patients with co-occurring depression and physical chronic health care needs, 2007-2010.

Authors:  Mónica Pérez Jolles; Lindsey Haynes-Maslow; Megan C Roberts; Stacie B Dusetzina
Journal:  Med Care       Date:  2015-08       Impact factor: 2.983

Review 2.  Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations.

Authors:  Emily Mendenhall; Brandon A Kohrt; Shane A Norris; David Ndetei; Dorairaj Prabhakaran
Journal:  Lancet       Date:  2017-03-04       Impact factor: 79.321

Review 3.  Depression in type 2 diabetes mellitus: prevalence, impact, and treatment.

Authors:  Katherine Semenkovich; Miriam E Brown; Dragan M Svrakic; Patrick J Lustman
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

4.  20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings.

Authors:  Taeho Greg Rhee; Mark Olfson; Andrew A Nierenberg; Samuel T Wilkinson
Journal:  Am J Psychiatry       Date:  2020-04-21       Impact factor: 18.112

5.  Antipsychotic Medication Treatment Patterns in Adult Depression.

Authors:  Tobias Gerhard; T Scott Stroup; Christoph U Correll; Cecilia Huang; Zhiqiang Tan; Stephen Crystal; Mark Olfson
Journal:  J Clin Psychiatry       Date:  2018 Mar/Apr       Impact factor: 4.384

6.  The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression.

Authors:  Shan Xing; Gregory S Calip; Alex D Leow; Shiyun Kim; Glen T Schumock; Daniel R Touchette; Todd A Lee
Journal:  J Diabetes Complications       Date:  2017-12-27       Impact factor: 2.852

7.  Indian Psychiatric Society multicentric study: Prescription patterns of psychotropics in India.

Authors:  Sandeep Grover; Ajit Avasthi; Vishal Sinha; Bhavesh Lakdawala; Manish Bathla; Sujata Sethi; D M Mathur; Puneet Kathuria; Sandip Shah; D Sai Baalasubramanian; Vivek Agarwal; Kamla Deka
Journal:  Indian J Psychiatry       Date:  2014-07       Impact factor: 1.759

Review 8.  The Nexus Between Diabetes and Depression: A Narrative Review.

Authors:  Salma Habib; Sai Lahari Sangaraju; Daniela Yepez; Xavier A Grandes; Ramya Talanki Manjunatha
Journal:  Cureus       Date:  2022-06-02

9.  Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials.

Authors:  Itaru Miura; Tadashi Nosaka; Hirooki Yabe; Katsuhiko Hagi
Journal:  Int J Neuropsychopharmacol       Date:  2021-03-17       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.